Edwards Lifesciences Corporation logo

Edwards Lifesciences Corporation (EW)

Market Closed
16 Jul, 20:00
NYSE NYSE
$
76. 14
-0.67
-0.87%
$
45.78B Market Cap
32.12 P/E Ratio
0% Div Yield
4,265,879 Volume
2.51 Eps
$ 76.81
Previous Close
Day Range
75.3 77.04
Year Range
58.93 89.86
Want to track EW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 6 days
Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength

Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength

On Tuesday, Edwards Lifesciences EW reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all product groups.

Benzinga | 5 months ago
EW Stock Up on Q4 Earnings and Revenue Beat, Margins Crash

EW Stock Up on Q4 Earnings and Revenue Beat, Margins Crash

Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart?

Zacks | 5 months ago
Edwards Lifesciences Corporation (EW) Q4 2024 Earnings Call Transcript

Edwards Lifesciences Corporation (EW) Q4 2024 Earnings Call Transcript

Edwards Lifesciences Corporation (NYSE:EW ) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mark Wilterding - Senior Vice President, Investor Relations Bernard Zovighian - Chief Executive Officer Scott Ullem - Corporate Vice President and Chief Financial Officer Daveen Chopra - Corporate Vice President, TMTT Larry Wood - Corporate Vice President and Group President of TAVR and SSH Conference Call Participants David Roman - Goldman Sachs Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Travis Steed - Bank of America Vijay Kumar - Evercore ISI Frederick Wise - Stifel Matthew Miksic - Barclays Matthew Taylor - Jefferies Joanne Wuensch - Citibank Mark Wilterding [Starts Abruptly] included in the press release and accompanying financial schedules and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections.

Seekingalpha | 5 months ago
Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics

Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 5 months ago
Edwards Lifesciences beats profit estimate on strength in heart devices

Edwards Lifesciences beats profit estimate on strength in heart devices

Edwards Lifesciences beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other medical devices.

Reuters | 5 months ago
Insights Into Edwards Lifesciences (EW) Q4: Wall Street Projections for Key Metrics

Insights Into Edwards Lifesciences (EW) Q4: Wall Street Projections for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

Zacks | 5 months ago
Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion

Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion

Edwards Lifesciences Corporation EW shares are trading higher on Thursday.

Benzinga | 5 months ago
Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth

Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth

Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.

Zacks | 5 months ago
Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 5 months ago
Should Edwards Lifesciences Stock Stay in Your Portfolio Now?

Should Edwards Lifesciences Stock Stay in Your Portfolio Now?

EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.

Zacks | 6 months ago
Is the Options Market Predicting a Spike in Edwards (EW) Stock?

Is the Options Market Predicting a Spike in Edwards (EW) Stock?

Investors need to pay close attention to Edwards (EW) stock based on the movements in the options market lately.

Zacks | 6 months ago
Levi & Korsinsky Reminds Edwards Lifesciences Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 13, 2024 – EW

Levi & Korsinsky Reminds Edwards Lifesciences Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 13, 2024 – EW

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.

Accesswire | 7 months ago
Loading...
Load More